ArticleMMWR. Morbidity and mortality weekly report2018
Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
Article in MMWR. Morbidity and mortality weekly report, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Barriers to Chagas Disease Screening among Primary Care Providers in the United States.The American journal of tropical medicine and hygiene · 2026Article
- Priced Out of Treatment: The Exorbitant Cost of Antiparasitic Drugs in the United States.Open forum infectious diseases · 2026Article
- An Evidence-Based Intervention to IncreaseOpen forum infectious diseases · 2025Article
- Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion.PLoS neglected tropical diseases · 2025Article
- Low risk for locally acquired Chagas disease in California: A review of human cases and triatomine submissions, 2013-2023.PLoS neglected tropical diseases · 2025Review
- Review on the Applications of Selected Metal-Based Complexes on Infectious Diseases.Molecules (Basel, Switzerland) · 2024Review
- Chagas disease in Oklahoma.The American journal of the medical sciences · 2022Review
- Evidence of likely autochthonous Chagas disease in the southwestern United States: A case series of Trypanosoma cruzi seropositive blood donors.Transfusion · 2022Article
- Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021.MMWR. Morbidity and mortality weekly report · 2022Article
- Chagas Disease in HIV-Infected Patients: It's Time to Consider the Diagnosis.The American journal of tropical medicine and hygiene · 2021Article
- Elevated Pediatric Chagas Disease Burden Complicated by Concomitant Intestinal Parasites and Malnutrition in El Salvador.Tropical medicine and infectious disease · 2021Article
- Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.PLoS neglected tropical diseases · 2020Article
- Chagas Disease in the New York City Metropolitan Area.Open forum infectious diseases · 2020Article
- Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening.The American journal of tropical medicine and hygiene · 2020Article
- Chagas Disease in the United States: a Public Health Approach.Clinical microbiology reviews · 2019Review
- Work-Related Trypanosoma cruzi Exposures.Journal of occupational and environmental medicine · 2019Article
- Proposed multidimensional framework for understanding Chagas disease healthcare barriers in the United States.PLoS neglected tropical diseases · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease (also known as American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi (1,2). Vectorborne transmission via skin or mucosal contact with the feces of infected triatomine bugs mainly occurs in rural areas of Latin America but has been reported in the southern United States (3). The parasite also is transmissible congenitally and via blood transfusion, organ transplantation, and accidental laboratory exposures. The two drugs used for treating Chagas disease are benznidazole and nifurtimox (1,2), which have been used in Latin America since the 1970s and 1960s, respectively. In the absence of commercially available drugs approved by the Food and Drug Administration (FDA), benznidazole and nifurtimox have been available exclusively through CDC, under Investigational New Drug (IND) treatment protocols. On August 29, 2017, FDA approved a benznidazole product (Chemo Research, SL, in care of Exeltis*) for treatment of Chagas disease (4), which became commercially available on May 14, 2018. Therefore, effective May 14, 2018, benznidazole is no longer available through the CDC-sponsored IND program. This report summarizes selected characteristics of patients for whom CDC released benznidazole through that program from October 2011, when the IND went into effect, until mid-May 2018. The majority of the 365 patients included in intention-to-treat analyses were chronically infected adults who were born and became infected in Latin America. Physician requests for benznidazole should now be directed to the drug company Exeltis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.